Researchers have demonstrated that the enzymatic activity of R5 receptor-type protein tyrosine phosphatases is a requisite for the maintenance of stem cell properties and tumorigenicity in glioblastoma cells and could be a promising drug target for treatment.
Researchers have uncovered the role of cellular prion protein (PrPC) in Neurofibromatosis Type 2 (NF2) related tumors, offering hope to neuro-tumor patients.
In a new study published in Scientific Reports, the investigators also reported a higher risk of glioblastoma in Alzheimer’s patients.
A new assay test for five cancer-associated genes with the goal of aiding prediction of neuroblastoma in children has been reported.
Investigators hope that their findings will assist in the development of targeted treatments for pediatric brain cancers.
This review explores the current literature on SRS treatment for both metastatic and benign intradural tumors, with a focus on differential use for intramedullary and intradural extramedullary neoplasms.
In this review, the authors discuss driving factors for the next generation of immunotherapy and target therapy, as well as how to increase the accuracy of the selection process for these therapies.
This review explores commonly used experimental models of GBM, recent improvements to these models and strategies for developing advanced models.
New study demonstrates how the enzyme, ACSS2, contributes to brain tumor growth in environments scarce of oxygen and nutrients.